These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35411376)

  • 1. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: Interim analysis of a multicentre cohort study.
    Kashiwado Y; Kimoto Y; Sawabe T; Irino K; Nakano S; Hiura J; Wang Q; Kawano S; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Akashi K; Ohshima S; Takeuchi T; Horiuchi T
    Mod Rheumatol; 2023 Mar; 33(2):367-372. PubMed ID: 35411376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients.
    Kashiwado Y; Kimoto Y; Ohshima S; Sawabe T; Irino K; Nakano S; Hiura J; Yonekawa A; Wang Q; Doi G; Ayano M; Mitoma H; Ono N; Arinobu Y; Niiro H; Hotta T; Kang D; Shimono N; Akashi K; Takeuchi T; Horiuchi T
    Rheumatology (Oxford); 2024 Mar; 63(3):725-733. PubMed ID: 37289506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
    Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
    Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
    Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Frodlund M; Nived P; Chatzidionysiou A; Södergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
    Vaccine; 2023 May; 41(20):3247-3257. PubMed ID: 37076360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Nephrol; 2023 Apr; 38(4):1099-1106. PubMed ID: 35913562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions.
    Krasselt M; Wagner U; Nguyen P; Pietsch C; Boldt A; Baerwald C; Pierer M; Seifert O
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI180-SI188. PubMed ID: 35143648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.
    Frommert LM; Arumahandi de Silva AN; Zernicke J; Scholz V; Braun T; Jeworowski LM; Schwarz T; Tober-Lau P; Ten Hagen A; Habermann E; Kurth F; Sander LE; Corman VM; Burmester GR; Biesen R; Albach FN; Klotsche J
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
    Sugihara K; Wakiya R; Shimada H; Kameda T; Nakashima S; Kato M; Miyagi T; Mizusaki M; Mino R; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Intern Med; 2022 Jul; 61(13):1953-1958. PubMed ID: 35466168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
    Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
    Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort.
    Mauro D; Ciancio A; Di Vico C; Passariello L; Rozza G; Pasquale MD; Pantano I; Cannistrà C; Bucci L; Scriffignano S; Riccio F; Patrone M; Scalise G; Ruscitti P; Montemurro MV; Giordano A; Vietri MT; Ciccia F
    Front Immunol; 2022; 13():901055. PubMed ID: 35784360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study.
    Mandl P; Tobudic S; Haslacher H; Karonitsch T; Mrak D; Nothnagl T; Perkmann T; Radner H; Sautner J; Simader E; Winkler F; Burgmann H; Aletaha D; Winkler S; Blüml S
    Ann Rheum Dis; 2022 Jul; 81(7):1017-1022. PubMed ID: 35304407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients.
    Nived P; Jönsson G; Settergren B; Einarsson J; Olofsson T; Jørgensen CS; Skattum L; Kapetanovic MC
    Arthritis Res Ther; 2020 Feb; 22(1):36. PubMed ID: 32087733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases.
    Yeo JG; Teh KL; Chia WN; Book YX; Hoh SF; Gao X; Das L; Zhang J; Sutamam N; Poh SL; Lim AJM; Tay SH; Yaung KN; Ong XM; Leong JY; Wang LF; Albani S; Arkachaisri T
    Rheumatology (Oxford); 2023 Sep; 62(9):3101-3109. PubMed ID: 36661304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.
    Pellicano C; Campagna R; Oliva A; Leodori G; Miglionico M; Colalillo A; Mezzaroma I; Mastroianni CM; Turriziani O; Rosato E
    Clin Rheumatol; 2022 Sep; 41(9):2755-2763. PubMed ID: 35614287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour.
    Ammitzbøll C; Thomsen MK; Andersen JB; Bartels LE; Hermansen MF; Johannsen AD; Mistegaard CE; Mikkelsen S; Vils SR; Erikstrup C; Hauge EM; Troldborg A
    Mod Rheumatol; 2023 Jul; 33(4):777-785. PubMed ID: 35860843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.